Skip to contentE
Editas Medicine, Inc.
E
EDITEditas Medicine, Inc. Q1 2019 · 10-Q
Revenue$2.07M$2.07M−47.3% vs Q1 2018 Net Income-$29.25M-$29.25MN/M vs Q1 2018 EPS Diluted-$0.60-$0.60N/M vs Q1 2018 Operating Income-$31,262,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Editas Medicine, Inc. · CIK 1650664 · Engraved from SEC EDGAR
Free Cash Flowderived-$29,721,000N/M Margins · derivedOperating margin-1511.0%−707.3 pt vs Q1 2018
Net margin-1413.7%−625.8 pt vs Q1 2018
ended Mar 31, 2019 · filed May 8, 2019 · 38 d after period end